Discussion
A novel treatment being developed by Vanda Pharmaceuticals for a single patient with Charcot-Marie-Tooth disease type 2S (CMT2S) — an ultrarare type of this genetic disorder — has been granted rare pediatric disease designation by the U.S. Food and Drug Administration (FDA). That regulatory status aims to incentivize…